ChromoGenics Q2 2023:  Weak on topline but better margins due better cost control and yield in production - Redeye
Bildkälla: Stockfoto

ChromoGenics Q2 2023: Weak on topline but better margins due better cost control and yield in production - Redeye

Weak on topline but better margins due better cost control and yield in production.

Börsvärldens nyhetsbrev